TYRA-300 - (SURF302)

May 13, 2026: Tyra Biosciences, Inc. (NASDAQ: TYRA) reported Q1 2026 financial results and provided a clinical update on oral FGFR3-selective inhibitor dabogratinib (formerly TYRA-300) under its “3x3” strategy across three Phase 2 programs aimed at supporting future regulatory submissions in LG-UTUC, IR NMIBC, and achondroplasia (ACH).

• SURF303 (Phase 2a/b, pivotal intent) in low-grade upper tract urothelial carcinoma (LG-UTUC): first patient dosed; initial results expected in 2027.
• SURF302 (Phase 2) in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (IR NMIBC): >20 patients enrolled; initial 3-month complete response data from both dose cohorts expected in August 2026.
• BEACH301 (Phase 2) in children ages 3–10 with achondroplasia: safety sentinel cohort enrolled; fourth dose level cleared with no notable safety events reported; initial sentinel cohort results (including 6-month average height velocity and safety) expected in Q4 2026.

The company also noted poster presentations for SURF302/SURF303 trials-in-progress at ASCO GU 2026 and EAU 26, planned AUA 2026 presentation, and preclinical ACH data presented in May 2026 at the Fusion Conference on FGFR Biology. Cash, cash equivalents and marketable securities were $383.5M as of March 31, 2026, with runway into 2H 2028.